Table 1.
S. no. of baby | GA (weeks) | B Wt. (Gms) | Type of ROP | PCA at time of 1st treatment (IV Aflibercept) | Zone at time of 1st treatment (IV Aflibercept) | Primary outcome (regression of ROP) and time | Nature of 2nd treatment | PCA in weeks and Zone at 2nd treatment | PCA, Zone and Nature of 3rd treatment | Secondary outcome (complete retinal vascularisation with no ROP Recurrence) |
---|---|---|---|---|---|---|---|---|---|---|
1 | 26 | 660 | HR Prethreshold | 34 | 2 | Yes, 1 week after injection | Laser | 45 (LE) 48(RE). Zone II | No | |
2 | 29 | 1050 | Threshold | 36 | 2 | Yes, 1 week after injection | Laser | 43 (LE) 45 (RE); Zone II | No | |
3 | 29 | 900 | AP ROP | 36 | 1 | Yes, 1 week after injection | None | Yes | ||
4 | 27 | 580 | AP ROP | 33 | 2 | Yes, 1 week after injection | Laser | 41, Zone II | No | |
5 | 31 | 1020 | AP ROP | 35 | 2 | Yes, 1 week after injection | None | Yes | ||
6 | 27 | 680 | AP ROP | 33 | 1 | Yes, 1 week after injection | Laser | 46, Zone II | No | |
7 | 28 | 906 | HR Prethreshold | 34 | 2 | Yes, 1 week after injection | None | Yes | ||
8 | 27 | 740 | Threshold | 33 | 2 | Yes, 1 week after injection | Laser | 40, Zone II | No | |
9 | 29 | 915 | AP ROP | 37 | 2 | Yes, 1 week after injection | None | Yes | ||
10 | 27 | 534 | HR Prethreshold | 35 | 2 | Yes, 1 week after injection | None | Yes | ||
11 | 26 | 670 | AP ROP | 35 | 1 | Yes, 1 week after injection | Laser | 48, Zone II | No | |
12 | 29 | 740 | AP ROP | 37 | 1 | Yes, 1 week after injection | IV Bevacizumab | 44, Zone I | 68 weeks Z1 Laser | No |
13 | 28 | 980 | AP ROP | 34 | 2 | Yes, 1 week after injection | IV Ranibizumab | 48, Zone II | 60 weeks Z2 Laser | No |
14 | 35 | 1400 | HR Prethreshold | 39 | 2 | Yes, 1 week after injection | None | Yes | ||
15 | 29 | 1050 | Threshold | 36 | 1 | Yes, 1 week after injection | Laser | 44, Zone II | No | |
16 | 33 | 1520 | AP ROP | 45 | 1 | Yes, 1 week after injection | Laser | 52, Zone II | No | |
17 | 26 | 725 | HR Prethreshold | 35 | 1 | Yes, 1 week after injection | Laser | 48, Zone II | No | |
18 | 28 | 675 | AP ROP NVE | 35 | 1 | Yes, 1 week after injection | IV Aflibercept | 44 (RE) 46 (LE); Zone I | 54 weeks Z2 Laser | No |
19 | 21 | 980 | AP ROP | 27 | 1 | Yes, 1 week after injection | IV ranibizumab | 48 (RE) 49 (LE); Zone II | No | |
20 | 31 | 1220 | HR Prethreshold | 35 | 1 | Yes, 1 week after injection | Laser | 40; Zone II | No | |
21 | 30 | 600 | HR Prethreshold | 36 | 2 | Yes, 1 week after injection | Laser (LE) None (RE) | 49, Zone II | No (LE) Yes (RE) |
|
22 | 30 | 1180 | AP ROP with NVE | 34 | 1 | Yes, 1 week after injection | None | Yes | ||
23 | 26 | 880 | Threshold ROP | 33 | 2 | Yes, 1 week after injection | Laser | 47, Zone II | No |